PD-L1 Binding Polypeptide Segmentation for Tissue Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, particularly those targeting the PD-1/PD-L1 pathway, face limitations such as immune-related toxicities and suboptimal tissue distribution due to the large size of monoclonal antibodies, necessitating the development of more effective and safer agents with high affinity for PD-L1 for therapeutic, prognostic, and diagnostic applications.
Innovation Solution
Development of multispecific PD-L1 binding polypeptides, including bispecific agents, with a defined PD-L1 binding motif that allows efficient interaction with PD-L1, potentially offering improved therapeutic and diagnostic capabilities while minimizing toxicities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used to target PD-1/PD-L1 pathway, then therapeutic efficacy is improved, but immune-related toxicities increase and tissue distribution becomes suboptimal due to large molecular size
Solution Approach 1:
The patent segments the large monoclonal antibody into smaller polypeptide components (e.g., nanobodies, single-domain antibodies) that retain PD-L1 binding capability. This segmentation reduces molecular size to improve tissue penetration while maintaining therapeutic efficacy and reducing immune-related toxicities associated with full-sized antibodies.
Solution Approach 2:
The invention extracts the essential PD-L1 binding function from the complete monoclonal antibody structure, isolating the minimal functional unit (polypeptide with PD-L1 binding motif) that can deliver therapeutic effect without the unnecessary bulk of the full antibody, thereby improving safety profile.
2Reliability
If monoclonal antibodies are used to target PD-1/PD-L1 pathway, then therapeutic efficacy is improved, but tissue distribution becomes suboptimal due to large molecular size
Solution Approach 1:
The patent divides the large monoclonal antibody into smaller polypeptide fragments (nanobodies, single-domain antibodies) that maintain PD-L1 binding affinity. This size reduction improves tissue distribution and penetration while preserving the essential therapeutic function through careful design of the binding motif.
3Volume of moving object
If smaller polypeptides are used to improve tissue distribution, then molecular size is reduced, but binding affinity and specificity for PD-L1 may be compromised
Solution Approach 1:
The invention focuses optimization on the local binding interface (PD-L1 binding motif) within the polypeptide, ensuring high affinity and specificity at this critical region while keeping the rest of the molecule small. This localized optimization maintains strong binding despite reduced overall molecular size.
Solution Approach 2:
The patent systematically optimizes parameters of the polypeptide sequence (amino acid composition, structural conformation, binding motif configuration) to maximize PD-L1 binding affinity within the constraints of small molecular size, achieving both compact structure and high binding strength.
Data Source
AI summary
The present disclosure relates to a class of engineered polypeptides having a binding affinity for programmed death-ligand 1 (PD-L1), and provides a PD-L1 binding polypeptide comprising the sequence ERNX4AAX7EIL X11LPNLX16X17X18QX20 WAFIWX26LX28D. The present disclosure also relates to the use of such a PD-L1 binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.